ALX Oncology Inc. — Rare Disease Pipeline | Kisho

Disease	Drug(s)	Designation	Approved
Smith-Lemli-Opitz syndrome	A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human IgG	Orphan Designation	-
acute myeloid leukemia	A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha variant 1 genetically linked to a modified and inactive Fc domain of human IgG	Orphan Designation	-
congenital lethal erythroderma	A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human IgG	Orphan Designation	-
malignant carotid body paraganglioma	A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human IgG	Orphan Designation	-
post 5-alpha-reductase inhibitors treatment syndrome	A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human IgG	Orphan Designation	-
post-treatment Lyme disease syndrome	A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human IgG	Orphan Designation	-
treatment-refractory schizophrenia	A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human IgG	Orphan Designation	-